HZNP - Horizon Therapeutics neuromyelitis drug Uplizna effective in analysis
An analysis of a phase 3 trial found that Horizon Therapeutics' (NASDAQ:HZNP) neuromyelitis optica spectrum disorder treatment Uplizna (inebilizymab) is effective for treating patients after one attack. Results showed among those with one attack prior to study initiation, 4.2% treated with Uplizna experienced an attack compared to 23.1% of those on placebo. Among those with more than one attack prior to the study, 12.4% of those on Uplinza experienced an attack compared to 48.7% in the placebo group. Uplinza was approved in 2020. Neuromyelitis optica is a central nervous system disorder that primarily affects the eye nerves and the spinal cord (myelitis). Read why Seeking Alpha contributor Out of Ignorance rates Horizon (HZNP) a hold.
For further details see:
Horizon Therapeutics neuromyelitis drug Uplizna effective in analysis